Totally 136 ALK-positive advanced NSCLC patients were screened for ALK rearrangement detected by tumor tissue or plasma Next-generation sequencing (NGS) at the Guangdong Lung Cancer Institute from January 2016 to December 2018. MET-aberrance was defined as c-Met overexpression performed by immunohistochemical(IHC) staining method with SP44 antibody and MET amplification assessed by tumor tissue or plasma Next-generation sequencing (NGS) or fluorescent in situ hybridization (FISH)The study found acquired MET-aberrance maybe a mechanism of acquired resistance to the second-generation ALK-TKIs for ALK-rearranged advanced NSCLC patients. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1379
Authors: Q. Deng, J. Kang, H. Wang, J. Yang, H. Yan, Z. Wang